Biotech | August 08, 2021
Strides Pharma reports Q1FY22 consolidated loss at Rs 205.2 Cr
The company expects revenue growth of 10-15 per cent in the US
The company expects revenue growth of 10-15 per cent in the US
India business contributes to a stellar performance
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
In the agreement, Marcor, an Azelis Americas company, will distribute the SPI Pharma product lines in the United States, and Azelis Canada Pharma Division will be responsible for the Canadian marketplace
Ibuprofen and Famotidine Tablets is an AB-rated generic therapeutic equivalent version of Horizon Medicines LLC’s Duexis Tablets, 800 mg/26.6 mg
This robust growth has come despite the raging pandemic for most part of the quarter
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
It had an estimated market size of US $ 32 million as of June 2021
Deal for 100 million doses with additional 100 million through 2023
Arrow is the marketing partner in US
Subscribe To Our Newsletter & Stay Updated
